Skip to main content
OpenTrials
Completed

NCT Number: NCT02939703

Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance

We propose to study the role of the gut microbiome in the development of obesity, and whether we can change the microbiome's contribution to host energy balance through diet. We have created a novel model that explicitly links the effects of microorganisms on human energy balance and modeled weight change, and will use the power of metabolic ward studies to measure small changes in energy absorption, total daily energy expenditure, and/or food intake that affect long-term weight gain or loss. By integrating clinical measurements, bioreactor experiments, and mathematical modeling, we will be able to describe cause-and-effect mechanisms that will enable a quantification of the microbiota's contribution to weight gain and inspire future studies on the interactions of diet, the gut microbiome, and human physiology.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Translational Research Institute for Metabolism and Diabetes

Orlando, Florida, 32804, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to communicate meaningfully with the investigator and legally competent to provide informed written consent
  • Age 18 - 45 years, inclusive
  • Weight stable (+/- 3 kg) during the 6 months prior to enrollment
  • BMI ≤ 30 kg/m2

Exclusion criteria

  • History or presence of cardiovascular disease (unstable angina, myocardial infarction or coronary revascularization within 6 months, clinically significant abnormalities on EKG, presence of cardiac pacemaker, implanted cardiac defibrillator)
  • History of type 1 or type 2 diabetes
  • Bleeding disorders
  • Acute or chronic infections
  • Hepatitis and/or cirrhosis
  • Severe asthma or chronic obstructive pulmonary disease
  • Renal insufficiency or nephritis
  • Thyroid dysfunction (suppressed TSH, elevated TSH if symptomatic, elevated thyroid stimulating hormone (TSH) if asymptomatic)
  • Uncontrolled hypertension (BP >160 mmHg systolic or >100 mmHg diastolic)
  • Prior bariatric surgery
  • Inflammatory bowel disease or malabsorption, swallowing disorders, suspected or known strictures, fistulas or physiological/mechanical GI obstruction, history of gastrointestinal surgery, Crohn's disease or diverticulitis
  • Participants with strict dietary concerns (e.g. vegetarian or kosher diet, multiple food allergies, or allergies to food we will provide them during the study)
  • Current use of polyethylene glycol (e.g. Dulcolax, Miralax, Gavilax)
  • Cancer within the last 3 years (except non-melanoma skin cancer or treated cervical carcinoma in situ)
  • History of depression within < 5 years from screening visit or which, in the opinion of a medical investigator, will impact the participant's ability to complete the study
  • History of eating disorders
  • Cushing's disease or syndrome
  • Untreated or inadequately controlled hypo- or hyperthyroidism
  • Active rheumatoid arthritis or other inflammatory rheumatic disorder
  • Pregnant or nursing females or females less than 6 months postpartum from the scheduled date of collection.
  • Tobacco use within the past 3 months
  • Metal implants (pace-maker, aneurysm clips) based on Investigator's judgment at Screening.
  • Unable to participate in MRI or MRS assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on Investigator's judgment at Screening.
  • Unable to tolerate MRI/MRS imaging or claustrophobia.
  • Nickel allergy.
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pretrial (screening) visit.
  • Intolerance to acetaminophen use.
  • History of regular alcohol consumption exceeding 7 drinks/week for female participants or 14 drinks/week for male participants (1 drink = 5 ounces [150 mL] of wine or12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months before screening.
  • Anemia (hemoglobin <12 g/dl in men, <11 g/dl in women)

Treatment and study plan

Diet

Other

Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.

Primary outcomes

  1. The primary endpoint for the protocol is the within-participant difference in fecal energy (via chemical oxygen demand, COD) normalized to the total daily energy intake and to the non-metabolizable marker PEG [COD (kcal) / PEG (g)].

    Time frame: Days 24-29 vs. Days 53-58

    Comparison within subject of control diet versus microbiome enhancer diet.

Sponsors and collaborators

Lead sponsor

AdventHealth Translational Research Institute

Other

Collaborators

  • Arizona State University

Registry information

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Oct 20, 2016
Registry last updated
Jun 30, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.